H.U.Group Holdings, Inc. · TSE:4544
H.U.Group — Q1 FY2023 Earnings Presentation
19 slides from H.U.Group's earnings presentation, Aug 8, 2023
Slide 1: Financial Results for the First Quarter of FY2023
Financial Results for The First Quarter of FY2023 (Ended June 30, 2023) Aug 8, 2023 （TSE: 4544）
Slide 2: Notes & references
Notes & references: * The financial information provided on this material has been prepared in accordance with Japanese GAAP except for EBITDA (Operating profit + Depreciation + Amortization of goodwill) which is a non-GAAP measure. * “Net Profit attributable to shareholders of the parent company” m
Slide 3: Financial Results for the First Quarter of FY2023
Financial Results for The First Quarter of FY2023 2
Slide 4: Consolidated Net Sales Changes
Consolidated Net Sales Changes (\ billion) 70 65.3 -7.26 12.3 1 -1.62 +0.17 56.6 2.9 1 Decrease in COVID-19 tests: -76% 50 53.0 Growth in base business: +1% 53.7 30 0 FY22 LTS IVD HS FY23 Q1 Q1 3 1. Net sales related to COVID-19 testing
Slide 5: Consolidated Operating Profit Changes
Consolidated Operating Profit Changes (\ billion) 12 (＋) Efficiency effect of profitability improvement (－) Profit decrease due to decrease in COVID-19-related tests (－) Marginal profit decrease due to increase in raw material costs 8.6 -4.52 (－) Profit decrease due to decrease in Covid-19-related 8
Slide 6: Consolidated Ordinary Profit/Loss & Net Profit/Loss
Consolidated Ordinary Profit/Loss & Net Profit/Loss Ordinary Profit/Loss Net Profit/Loss (\ billion) (\ billion) 9 8.5 9 5.6 6 6 3 3 -1.5 -1.1 0 0 FY22 FY23 -3 FY22 FY23 -3 Q1 Q1 Q1 Q1 Major non-operating factors Major extraordinary factors Foreign exchange gains +\0.74 B Gain on sale of busines
Slide 7: Quarterly Performance Trend
Quarterly Performance Trend Net sales EBITDA, OP (\ billion) Net sales related to (\ billion) Net sales EBITDA Operating Profit 90 COVID-19 testing 45 75.1 70.2 68.8 66.9 62.5 61.9 63.5 64.1 65.3 23.2 59.9 56.6 60 54.7 18.7 11.8 12.3 15.0 11.4 30 9.5 12.2 12.9 6.4 2.9 43.9 6.2 53.0 52.3 53.0 53.8 55
Slide 8: LTS
LTS Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 60 18 FY22 FY23 Variance Q1 Q1 Net sales 43.4 36.1 -7.26 -16.7% 43.4 41.7 Off-site 32.0 29.2 -2.77 -8.7% 1.3 39.7 38.4 40 1.6 2.0 36.1 12 FMS/Branch Others 10.1 1.3 6.1 0.8 -3.98 -0.51 -39.5% -39.9% 10.1 7.
Slide 9: IVD
IVD Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 24 24 FY22 FY23 Variance 20.2 20.4 Q1 Q1 Net sales 15.0 13.4 -1.62 -10.8% Lumipulse 7.1 6.1 -0.96 -13.6% 3.5 4.0 Japan 6.1 5.3 -0.77 -12.6% 15.0 14.4 Overseas 1.0 0.8 -0.19 -19.8% 13.4 CDMO etc. 5.4 5.2 -0.
Slide 10: HS
HS Quarterly Results YoY Comparison Net sales EBITDA, OP (\ billion) (\ billion) (\ billion) 10 4 FY22 FY23 Variance Q1 Q1 Net sales 7.0 7.2 +0.17 +2.4% 7.0 6.8 6.8 7.1 7.2 Sterilization 5.5 5.6 +0.14 +2.5% Home-visiting, 1.6 1.5 1.6 +0.03 +2.0% 1.5 1.6 welfare 1.5 1.6 EBITDA 0.80 11.4% 0.74 10.3% -
Slide 11: Consolidated Results for FY2023 Q1
Consolidated Results for FY2023 Q1 (\ billion) FY2022 Q1 FY2023 Q1 Profit Profit Variance Results Results ratio ratio Net sales 65.3 56.6 -8.71 -13.3% LTS 43.4 36.1 -7.26 -16.7% IVD 15.0 13.4 -1.62 -10.8% HS 7.0 7.2 +0.17 +2.4% 1 OP 8.6 13.1% -1.7 -3.0% -10.29 ー LTS 1.7 3.9% -2.8 -7.8% -4.52 ー IVD 7
Slide 12: Cash and Deposits / Interest-bearing Debts
Cash and Deposits / Interest-bearing Debts (\ billion) FY2023 Q1 FY2022 Q1 Cash and deposits Short-term debts Interest- 46.5 Long-term debts 44.2 39.7 bearing Cash and 32.7 debts Lease debts Corporate deposits bond 3.7 3.5 3.6 5.5 Interest- Net interest-bearing debt balance bearing debts 18.7 15.0 2
Slide 13: Analysis of Consolidated Cash Flows (FY2023 Q1)
Analysis of Consolidated Cash Flows (FY2023 Q1) Investment cash (\ billion) Operating cash flows -6.2 Others -4.0 flows -3.9 Free cash flows -10.1 1 1 -33.0 -14.1 (Increase in net interest-bearing debts） -47.1 March 31, 2023 June 30, 2023 Operating capital -0.0 -Decrease in Sales credit/ -33.0 Contr
Slide 14: Analysis of Consolidated Cash Flows (FY2022 Q1)
Analysis of Consolidated Cash Flows (FY2022 Q1) Investment cash (\ billion) Operating cash flows +6.1 Others -3.2 flows -7.3 Free cash flows -1.2 1 1 -26.5 -4.4 （Increase in net interest-bearing debts） -30.9 March 31, 2022 June 30, 2022 Decrease in Sales credit/ Contract assets Decrease in Increase
Slide 15: Status Update in FY2023 Q1
Status Update in FY2023 Q1 FES y.u.croup
Slide 16: Consolidated Operating Profit: Gap, Outlook and Measures
Consolidated Operating Profit: Gap, Outlook and Measures # Item Initial forecast Gap to initial forecast Outlook and measures PCR tests and ESPLINE ・Proactively capture the demand of A certain level of demand to demand below expectation quantitative antigen test 1 Covid-19-related sales be sustained
Slide 17: AkirunoCube Costs and Effects
AkirunoCube Costs and Effects Anticipating higher costs and possible reduction in efficiency gains due to delays in reporting some general test results, but the impact on business performance for this fiscal year is being evaluated (\ billion ） FY23 full-year FY23 Q1 Forecast Result Current estimate
Slide 18: Third-Party Evaluations and Participation in Initiatives
Third-Party Evaluations and Participation in Initiatives Chosen to be on the following indices: Selected to be on METI’s list of • FTSE4Good Index Series (first time) Digital Transformation Stocks • FTSE Blossom Japan Index (first time) 2023 • FTSE Blossom Japan Sector Relative Index (second consecu
Slide 19: Contact information
【Contact information】 IR/SR Department Email : [email protected] Disclaimer regarding forward-looking statement: The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncerta
H.U. Group Holdings — Q1 FY2023 Earnings Presentation on 6ix